Trial Profile

First-in-human (FIH), multicenter, open-label, phase I clinical trial of ABSK051 monotherapy in patients with any types of advanced solid tumors and ABSK051 in combination with Tislelizumab in patients with selected tumor types, such as lung cancer, colorectal cancer (CRC), ovarian cancer, and pancreatic ductal adenocarcinoma (PDAC).

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 20 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ABSK 051 (Primary) ; Tislelizumab (Primary)
Indications Adenocarcinoma; Colorectal cancer; Lung cancer; Ovarian cancer; Pancreatic cancer; Pancreatic ductal carcinoma; Solid tumours
Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics; Therapeutic Use

20 Nov 2023 New trial record
09 Nov 2023 According to an Abbisko Therapeutics media release, the company has obtained the clinical trial approval from the National Medical Products Administration (NMPA) of the People's Republic of China.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com